PF-Atlas › Clinical Trials › NCT05596786
Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial
Rituximab · Phase 3
Registry ID
NCT05596786
Phase
Phase 3
Status
Recruiting
Drug / intervention
Rituximab
Sponsor
University Hospital, Tours
Start
2023-01-16
Enrollment
126
Locations
1
About this trial
The main objective of the EvER-ILD2 study is to evaluate the efficacy on lung function at 6 months of one course rituximab (2 infusions) comparatively to one course of placebo (2 infusions) in a broad range of progressive ILD patients with inflammatory component.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05596786 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.